Background-Repeated myocardial microinjuries lead to collagen deposition and fibrosis, thereby increasing the risk of clinical heart failure. Little is known about the longitudinal association between increases in myocardial injury and the biology of collagen synthesis and deposition. Methods and Results-Repeated measures of highly sensitive cardiac troponin T (cTnT) were obtained in participants of the Cardiovascular Health Study (N=353; mean age, 74±6 years; 52% women) at baseline and at 3 years follow-up. Biomarkers of collagen metabolism were obtained at follow-up and included carboxyterminal propeptide of procollagen type I, carboxyterminal telopeptide of type I collagen, and aminoterminal propeptide of procollagen III. Multivariable linear regression analyses were used to examine the association between baseline cTnT and changes in cTnT with collagen metabolism markers at follow-up adjusting for demographics, heart failure status, and cardiovascular risk factors. Results indicated that cTnT increases over 3-years were significantly associated with higher levels of carboxyterminal telopeptide of type I collagen (β=0.22, P<0.001) and aminoterminal propeptide of procollagen III (β=0.12, P=0.035) at follow-up when adjusting for demographic, clinical, and biochemical covariates including baseline cTnT. These associations were stronger in patients with heart failure than in control subjects.
M yocardial fibrosis plays an important role in increased left ventricular (LV) stiffness, elevated pulmonary venous pressure, and decreased LV stroke volume reserve. [1] [2] [3] [4] These conditions may result in clinical systolic heart failure (HF) or HF with preserved LV function. Myocardial infarction with necrosis of large amounts of myocardium leads to replacement fibrosis. Biological processes related to microinjury can lead to myocardial fibrosis in the absence of myocardial infarction and increase the risk of HF. 5 The present study addresses the associations of myocardial micro-injury, reflecting injury or necrosis of few myocytes, with collagen metabolism markers.
Editorial see p 394 Clinical Perspective on p 413
Myocardial microinjury can now be accurately measured with a highly sensitive cardiac troponin T (cTnT) assay with levels below those used to define an acute myocardial infarction. 6, 7 We recently demonstrated that high sensitivity cTnT can be detected in 66% of individuals aged ≥65 years and that increases in cTnT over time are predictive of incident HF and cardiovascular mortality. 8 Microinjury activates matrix metalloproteinase, thereby acting as a potent collagen turnover stimulating factor. Type I and III collagens are the predominant fibrillar collagens in normal and diseased myocardium. 3, [9] [10] [11] [12] Biomarkers of collagen metabolism relevant to fibrosis include carboxyterminal propeptide of procollagen type I (PIP), a marker of type I collagen synthesis; carboxyterminal telopeptide of type I collagen (CITP), a marker of degradation of type I collagen; and aminoterminal propeptide of procollagen III (PIIINP), a marker of synthesis and degradation of type III collagen. [13] [14] [15] Although markers of collagen metabolism derived from blood samples are not cardiac-specific, 16 histological evidence indicates that serum PIP reflects myocardial fibrosis in HF and other cardiac conditions, 17 whereas such evidence is still pending for CITP and PIIINP.
In addition, biological processes related to microinjury can lead to myocardial fibrosis in the absence of myocardial infarction and increase the risk of HF. 5 The present study addresses the associations of myocardial microinjury, reflecting injury or necrosis of few myocytes, with collagen metabolism markers.
Methods

Participants
The study included participants in the Cardiovascular Health Study (CHS) in whom collagen metabolism markers and serial cTnT levels were measured as part of a nested case-control study of HF. The associations between changes in cTnT and collagen metabolism markers were examined in individuals with HF, individuals with cardiovascular disease risk factors (hypertension, diabetes, or hypercholesterolemia), and individuals without these cardiovascular disease risk factors. The HF-free control groups were examined to determine whether changes in cTnT are associated with collagen metabolism markers before the onset of clinical HF and to minimize confounding by HF-related medications (eg, angiotensin-converting enzyme inhibition and β-adrenergicblocking agents).
The CHS is a prospective, community-based, epidemiological observational investigation designed to assess cardiovascular risk factors and outcomes in persons aged ≥65 years. The design and examination of the CHS have been published previously. 18 Briefly, 5201 participants aged ≥65 years were enrolled in 1989 to 1990 with an additional cohort of 687 ethnic minority participants enrolled in 1992 to 1993. Exclusion criteria for the total CHS cohort were: hospice treatment, wheelchair-bound in the home, and radiation or chemotherapy for cancer. For purposes of the present study, history of chronic liver disease or pulmonary disease was used as an additional exclusion criterion to minimize confounding effects of these diseases on the biochemical measures related to fibrosis, as described previously. 19 Figure 1 displays the inclusion flowchart of the 353 participants in this study. Using a case-control design based on HF status, collagen metabolism markers were assessed in a subcohort of the CHS (N=880; 638 in 1992-1993 and 242 in 1996-1997). 19, 20 For this case-control study, control subjects were frequency-matched at a 1:1 ratio based on sex and age. 19 The cTnT levels were obtained for the full CHS cohort with sufficient sample volume from samples collected in 1989 to 1990, 1992 to 1993, and 1994 to 1995 (minority cohort only). For the 1992 to 1993 collection, that is, when cTnT and collagen metabolism markers were collected simultaneously, 153 participants did not have remaining samples for the concurrent assessment of collagen metabolism markers and cTnT. Of the 485 patients with concurrent data for collagen metabolism markers and cTnT, 11 did not have a preceding cTnT measure (these were enrolled as part of the minority cohort) and 121 did not have sufficient sample left for baseline assessments (1989) (1990) , leaving 353 participants for the present study. Patient characteristics are shown in Table 1 .
All clinical and biochemistry measures were obtained at the same evaluation visit for each patient when collagen metabolism markers and cTnT were assessed (ie, 1992-1993) to ensure simultaneous assessments of collagen metabolism markers, cTnT, and covariates. Issues concerning the stability of the collagen metabolism markers and cTnT related to long-duration sample storage are described subsequently. 21, 22 The presence of HF was determined by expert adjudication of clinical records as described previously. 23 In brief, self-report of a physician diagnosis of HF was followed by confirmational review of the participant's medical records. HF was defined as present if a diagnosis of congestive HF by a physician and treatment of HF were documented (ie, current prescription for a diuretic agent and either digitalis or a vasodilator). In addition, symptoms, signs, and chest x-ray findings of congestive HF were reviewed by the CHS Events Committee. Congestive HF was termed "definite" if the medical record data were complete or nonambiguous. Patients who had an adjudicated HF diagnosis and with available biochemistry data for fibrosis markers and repeated cTnT (N=101) were compared with 2 control groups: (1) control subjects with cardiovascular disease risk factors but without HF (N=99); and (2) healthy control subjects without HF, coronary heart disease, hypertension, diabetes mellitus, or hypercholesterolemia in 1992 to 1993 (N=153).
Blood Chemistry
Phlebotomy methods, blood processing, and handling of samples have been described previously. 24, 25 Aliquots were frozen at −70˚C until analysis for collagen metabolism, cTnT, and other biological measures. Collagen metabolism markers were analyzed in 2005 at the University of Vermont 19 and cTnT assays were conducted in 2010 at the University of Maryland. 8 Technologists were blind to participants' clinical status and other biochemical data.
Collagen Metabolism Markers
Serum CITP was measured using a radioimmunoassay from Orion Diagnostica. Interassay and intra-assay variability are 3.5% to 9.5% and 5.6% to 9.0%, respectively, and the lower detection limit is 0.4 μg/L. Serum PIIINP was determined by a coated tube radioimmunoassay, as described previously by Risteli and colleagues, 26 using commercial antisera specifically directed against the terminal amino terminal peptide (Orion Diagnostica). The interassay and intra-assay variations for determining PIIIP are <6%, and the lower detection limit is 1.5 ng/mL. PIP was measured using enzyme immunoassay (Takara Mirus Bio Inc, Madison, WI). The assay range is 10 to 640 ng/mL with a lower detection limit of 10 ng/mL. Intra-assay and interassay coefficients of variation range from 4.5% to 7.4% and 4.3% to 6.3%, respectively.
Stability of the collagen metabolism assays was determined by comparing levels of control subjects obtained in 1992 to 1993 versus control subjects assessed in 1996 to 1997 adjusting for age. Analysis of covariance indicated that the age-adjusted mean levels were stable for all 3 markers (PIP=406.06±14.44 ng/mL versus 419.34± 15.59 ng/mL P=0.24; CITP 5.09±0.25 μg/L versus 5.02±0.30 μg/L, P=0.79; and PIIINP 3.93±0.15 μg/mL versus 4.35±0.18 μg/mL, P=0.11, for 1992-1993 versus 1996-1997, respectively).
Cardiac Troponin
Measurements were performed on serum using highly sensitive cTnT reagents on an Elecsys 2010 analyzer (Roche Diagnostics, Indianapolis, IN) as described previously. 8 The analytic measurement range is 3 to 10 000 pg/mL with the 99th percentile cutoff from a healthy reference population (n=616) 13.5 pg/mL and the 10% interassay coefficient of variation concentration close to or less than the 99th percentile of the reference population. 7 The assay is stable over time with an estimated degradation rate of 0.36 ng/L per year. 22 In the present study, we compared the cTnT levels at baseline (1989-1990) and 7 years later (1992-1993) in the subgroup of healthy participants (N=153; time delays of 20-21 and 17-18 years, respectively). There was no significant difference in cTnT levels over this 3-year period (median change, 0.00; interquartile range, −1.12 to 2.66 pg/mL; age-adjusted cTnT levels were 6.90; 95% CI, 5.63-8.16 pg/mL and 7.07; 95% CI, 6.23-7.91 pg/mL; P=0.847 based on analysis of covariance).
Inflammation
High sensitivity C-reactive protein (CRP) was assessed with an ultrasensitive enzyme-linked immunosorbent assay using purified protein and polyclonal anti-CRP antibodies 27 with a interassay coefficient of variation of <5%.
Covariates
Clinical variables included cardiovascular risk factors (hypertension, diabetes mellitus, smoking status, physical activity levels, and body mass index), history of coronary heart disease (defined as myocardial infarction, history of revascularization, or angina), and echocardiographically determined LV ejection fraction and LV mass. Other disease-related covariates included osteoarthritis and arthritis, history of stroke, and obstructive peripheral artery disease because these conditions are associated with elevated collagen metabolism markers (clinically significant liver and pulmonary disease were used as exclusion criteria because these conditions substantially influence collagen metabolism marker assays). Prevalent disease status was updated for the 1992 to 1993 visit based on adjudicated incident events throughout the study. Echocardiograms were used to determine systolic and diastolic measures and were analyzed at a central core echocardiography laboratory (J.S.G.). Qualitative LV ejection fraction was estimated based on echocardiographic data obtained either at the baseline CHS examination or at the point of care as abstracted from clinical records.
Covariates based on blood chemistry included total cholesterol, high-density lipoprotein and low-density lipoprotein, creatinine (to calculate estimated glomerular filtration rate), and N-terminal protype B natriuretic peptide as described previously. 24, 25, 28 
Statistical Analyses
Data are presented as mean±SD for continuous variables, median, and interquartile range for biochemistry measures and percentages for categorical variables. The 3 groups of participants (healthy control subjects, control subjects with cardiovascular disease risk factors, and patients with HF) were compared using analysis of variance for continuous data with logarithmic transformations for nonnormally distributed variables, nonparametric Kruskal-Wallis test for cTnT (to handle the participants with below detection rate values, set at 2.99 pg/mL), or χ 2 tests for categorical variables.
Associations between cTnT and myocardial collagen metabolism markers were examined using nonparametric correlation coefficients (Spearman ρ). Multivariable models were then used to examine whether association between cTnT and collagen metabolism markers remained significant when adjusting for covariates obtained at the same time point (1992) (1993) . A hierarchical approach was used, examining the role of 3 covariate sets: (1) demographics (age, sex, race [black versus other], and group status [HF, control with traditional cardiovascular risk factors, healthy control subject]); (2) traditional cardiovascular risk factors were selected from validated risk scores for cardiovascular mortality 29 : history of coronary heart disease, systolic and diastolic blood pressure, use of antihypertensive medications, diabetes, smoking, and total and high-density lipoprotein cholesterol; and (3) inflammation (CRP). Participants were divided into 3 categories of incremental cTnT concentration based on tertiles, (<3.00-4.75 pg/mL; ≥4.75 to <11.10 pg/mL; and ≥11.10 pg/mL) and analyses of variance were then used to compare cTnTbased groups on collagen metabolism markers. The group (HF, control with cardiovascular risk factors, healthy control subject)×cTnT level (per tertile) interaction term was used to determine whether associations between cTnT with collagen metabolism markers differed across groups.
Change in cTnT concentration was considered using continuous scores and based on a ≥50% increase in cTnT from baseline (1989) (1990) to follow-up (1992-1993) . Those with ≥50% relative increase in cTnT were compared with those with longitudinal change of <50% with regard to collagen metabolism markers levels, adjusting for baseline cTnT and for the risk factors described previously. The choice of a ≥50% relative change threshold was specified a priori based on a prior study of short-term change in cardiac troponin I (measured with a highly sensitive assay) in healthy adults. 30 At baseline, 94 of 353 had cTnT values below detection (<3.0 pg/mL); for change scores, these were set at 2.99 pg/mL. Analyses were repeated at the same time as excluding participants with undetectable levels, which revealed the same results (data not shown).
Because biological correlates of systolic HF may differ from HF with preserved ejection fraction, subgroup analyses were performed for these 2 subgroups. Data were analyzed using STATA and SPSS/ PASW. A probability value of <0.05 was used to indicate statistical significance. Table 1 presents participant characteristics. Age and sex distributions were comparable across the HF and control groups, reflecting successful matching procedures. Patients with HF differed from the control group with cardiovascular risk factors on the following measures: history of coronary artery disease, stroke, LV ejection fraction, N-terminal protype B natriuretic peptide, and CRP. Among patients with HF, 54 of 101 (54%) had HF at study entry and 57 (56%) developed HF between baseline assessment (1989) (1990) ) and measurement of collagen metabolism at follow-up (1992-1993).
Results
Participant Characteristics
Patients with HF had significantly higher CITP, PIIINP, but not PIP levels than control subjects, as documented previously. 19 The cTnT levels were also higher in patients with HF than control subjects. The 2 control groups did not differ on collagen metabolism markers (probability values >0.20), whereas cTnT levels were higher in control subjects with risk factors versus healthy control subjects (P=0.004).
Associations Between cTnT and Collagen Metabolism Markers
Significant cross-sectional associations (collected in 1992-1993) were found between cTnT and the collagen metabolism markers CITP and PIIINP but not PIP ( Table 2) .
The collagen metabolism markers (CITP and PIIINP) were correlated with selected demographic and clinical measures (most consistently with older age, lower total cholesterol, lower high-density lipoprotein, and higher CRP) and cTnT with older age, male sex, diabetes, lower cholesterol and lower high-density lipoprotein. Multivariable regression analyses showed that cTnT was significantly associated with CITP (β=0.35, P<0.001) and PIIINP (β=0.22, P=0.003) but not PIP (β=−0.03, P=0.73), adjusting for age, sex, race, HF/control status, coronary heart disease, systolic and diastolic blood pressure, antihypertensive medication use, diabetes, smoking status, total cholesterol, high-density lipoprotein, and CRP (overall model R 2 =0.23, 0.15, and 0.09, respectively).
The addition of CRP did not significantly change the model (ΔR 2 <0.05; P>0.10). The correlations between CRP levels with collagen metabolism markers or cTnT were also nonsignificant (r<0.10), suggesting that inflammation does not play a primary role in the association between cTnT and collagen metabolism markers.
When examining tertiles of cTnT, the pattern of results was similar with significant main effects for CITP (P<0.001) and PIIINP (P<0.001) but not PIP (P=0.40). Consistent with the analyses of continuous collagen metabolism marker levels, associations with cTnT tended to be stronger in patients with HF than control subjects as shown in Figure 2 (P interaction =0.061 for CITP and P interaction =0.092 for PIIINP).
Longitudinal Changes in cTnT Over 3 Years as a Predictor of Collagen Metabolism Markers
The median cTnT increase (Δ) from baseline (1989) (1990) to follow-up (1992-1993) was 1.16 (interquartile range, −0.85 to 4.24 pg/mL) for the complete sample. Increases were higher in patients with HF (Δ=3.10; interquartile range, 0.23-13.05; P<0.001) than control subjects (healthy control subjects Δ=0.00; interquartile range, −1.12 to 2.66 pg/mL) and control subjects with cardiovascular risk factors (Δ=1.22; interquartile range, −1.30 to 4.33 pg/mL). Of the 94 participants with below-detectable cTnT levels (<3.00 pg/mL) at baseline, 43 (46%) continued to have undetectable levels at follow-up, an increase in cTnT >50% was observed in 120 (34%) of the participants, of whom 51 (43%) had initially undetectable cTnT levels. The prevalence of ≥50% increase in cTnT was more common in HF than control subjects (healthy control subjects 28%, control subjects with cardiovascular risk factors 33%, and HF 44%; P=0.039). As shown in Table 3 , the increase in cTnT from baseline to 3 years follow-up was significantly associated with higher levels of collagen metabolism markers at follow-up. Furthermore, an increase of 50% or more was associated with higher CITP and PIIINP levels at follow-up (CITP P=0.006; PIIINP P=0.029; PIP P=0.75). As shown in Figure 3 , the predictive value of a ≥50% increase in cTnT was stronger in patients with HF than in control subjects for CITP (P interaction =0.050) and PIIINP (P interaction =0.011) but not PIP (P interaction =0.61).
Multivariable analyses indicated that increases in cTnT were independently predictive of CITP (β=0.23, P<0.001) adjusting for demographic and biomedical covariates including baseline cTnT (multivariable model R 2 =0.23). Increases in cTnT were also independently predictive of PIIINP in multivariable analyses (β=0.12, P=0.030), adjusting for covariates (multivariable model R 2 =0.17), whereas adjusted models for PIP did not show significant associations with D cTnT (β=0.03, P=0.67; multivariable model R 2 =0.15).
Subgroup analyses based on HF status revealed similar results for patients with systolic HF versus HF with preserved ejection (1992) (1993) . D cTnT from samples collected at baseline (1989) (1990) ) and follow-up (1992) (1993) .
Positive correlations indicate that an increase in cTnT was associated with higher collagen metabolism marker levels.
cTnT indicates cardiac troponin T; CVD, cardiovascular; HF, heart failure; CITP, carboxyterminal telopeptide of type I collagen; PIIINP, aminoterminal propeptide of procollagen III; PIP, procollagen type I. *P<0.01. fraction with significant correlations for concurrent cTnT as well as changes in cTnT as related to CITP (P<0.01). PIIINP was associated with concurrent cTnT (P=0.033) and Δ cTnT (P=0.015) in HF with preserved ejection fraction and only with concurrent cTnT (P=0.033) but not Δ cTnT (P=0.48) in systolic HF. Associations for PIP remained nonsignificant in these subgroup analyses.
Discussion
This study shows that myocardial injury at the microlevel is associated with pathophysiological processes that are critically involved in tissue repair and fibrosis. Specifically, higher levels of cTnT, a high-sensitive marker of myocardial damage, were associated with collagen deposition. Moreover, increases in cTnT over time are related to higher levels of 2 primary collagen metabolism markers, CITP and PIIIINP, and these associations were independent of cardiovascular risk factors. This study also indicates that associations between myocardial tissue damage at the microlevel and dysregulated collagen metabolism are stronger in patients with HF than in control subjects without HF. Myocardial injury from ischemia, physical damage, infections, or biochemical origins may result in cell death and scar. Serum measures of cTnT reflect these microinjury-related processes and previous research from our group has demonstrated that longitudinal increases in cTnT are predictive of incident HF and mortality in individuals aged ≥65 years. 8 The biological processes involved in tissue repair involve collagen production and collagen deposition. These processes play an essential role in myocardial fibrosis and subsequent cardiac remodeling leading to HF. [9] [10] [11] [12] Recent studies also report the prognostic value of myocardial fibrosis identified by cardiac MRI in both ischemic and nonischemic cardiomyopathy. 31, 32 The present study showed that cTnT is cross-sectionally associated with elevated CITP and PIIINP levels and in addition that increases in cTnT over a 2-year period independently predict higher levels of these collagen metabolism markers at follow-up.
Associations between cTnT and collagen metabolism markers were significant for CITP and PIIINP but not PIP. This finding seems at variance with studies demonstrating a specific association between PIP and HF. 11, 16, 33, 34 Although histological evidence suggests that serum PIP reflects myocardial fibrosis in HF, 16 evidence also indicates that PIP is also elevated in other clinical conditions such as liver disease 35 and osteoporosis. 36 Furthermore, other studies have not found significant associations between PIP with prevalent HF 12, 15 and a prior report based on this cohort has also indicated that PIP was not significantly related to HF. 19 PIP is a marker of type I collagen synthesis and plays an essential role in the balance between collagen deposition and degradation. One explanation of the lack of association between cTnT with PIP is that CITP and PIIINP are better indicators of dysregulation of the collagen deposition process, whereas PIP reflects the initial synthesis process that may not be dysfunctional in HF. It is possible that type I collagen destruction exceeds its synthesis or that a shift from type I to type III collagen synthesis develops over time. Other possible explanations include assay-related issues or a plateau of collagen type I synthesis in this particular study sample (all participants were ≥65 years of age).
Myocardial ischemia and neurohormonal activation (including the renin-angiotensin-aldosterone axis dysregulation and sympathetic nervous system activation) may lead to clinical HF. [1] [2] [3] [4] In addition, inflammation acts as a collagen synthesis-stimulating factor and also results in excess deposition of collagen in the extracellular matrix of the myocardium and other tissues. 37 The present data did not find significant correlations between elevated CRP levels with collagen metabolism markers or cTnT in cross-sectional and longitudinal analyses (r <0.10). Metalloprotease activation can lead to fibrosis, both in chronic 9 as well as acute 38 conditions. However, CITP can also be released in response to collagen formation, and the net effect on interstitial collagen remains unknown. Although matrix metalloproteinases are proteolytic enzymes that degrade collagen in extracellular matrix, matrix metalloproteinase-9 also activates profibrotic pathways. Moreover, inflammation upregulates matrix metalloproteinases, and the remodelling of interstitium likely involves both collagen degradation and synthesis. 37 The present article indicates that it is likely that microinjury plays a contributing role in the collagen metabolism and possibly fibrosis processes. Basic science and epidemiological and clinical intervention studies are needed to disentangle the relative importance of microinjury on cardiac fibrosis, particularly as related to the pathophysiology of HF. Future longitudinal studies are also needed to identify the biological pathways including serial assessments of metalloproteases and tissue inhibitor of matrix metalloproteinases to identify the biological processes that precede myocardial dysfunction and clinical HF.
The prospective nature of this study is unique and a major strength of the design. However, a few limitations need to be considered. Collagen metabolism markers were obtained in a subset of the CHS cohort with a focus on patients with HF. Control subjects were selected using frequency-based matching for age, sex, and race. This is a potential strength when comparing patients with HF with control subjects, but this selection strategy may have introduced a biased control group, which potentially interferes with generalizability. Examining myocardial injury and collagen metabolism markers in control groups without myocardial disease may need a restriction of range related to the low-grade nature or absence of the target fibrosis-related pathophysiological processes. The study also did not use biopsies or MRI to directly measure cardiac fibrosis, which was not feasible in this population-based study. Another limitation is that the baseline assessments in the CHS do not include collagen metabolism markers, and simultaneous assessments of cTnT and collagen metabolism markers were only feasible in the 1992 to 1993 examination year. This study could therefore only examine whether changes in cTnT preceded increases in collagen metabolism markers, whereas the possibility of ruling out a reverse pattern of associations remains to be examined.
The clinical implications of this study include the potential benefits of serial assessments of multiple biomarkers that reflect different components of the multifactorial disease processes in HF and other cardiovascular diseases. Assessments of cTnT may identify patients in whom the biology of collagen metabolism is dysregulated resulting in increased myocardial fibrosis. Myocardial fibrosis precedes increased ventricular stiffness, which in turn may lead to poor cardiac contractility and clinical HF. Trials examining aldosterone antagonists support the role of fibrosis in HF because these agents decrease collagen formation and improve clinical outcomes. [39] [40] [41] Thus, serial assessments of cTnT combined with collagen metabolism markers may increase our understanding of the pathophysiological fibrotic processes involved in HF. Prospective studies are needed to determine whether the combined use of serial microinjury and collagen metabolism markers are useful for patient risk stratification and future guidance for treatment strategies in targeted populations at risk of HF.
